Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Dicerna Pharmaceuticals, Inc.    DRNA

DICERNA PHARMACEUTICALS, INC.

(DRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Dicerna Pharmaceuticals : to Participate in the Chardan 4th Annual Genetic Medicines Conference

share with twitter share with LinkedIn share with facebook
09/28/2020 | 05:07pm EDT

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will participate in a virtual fireside chat at the Chardan 4th Annual Genetic Medicines Conference on Mon., Oct. 5, 2020 at 1:30 p.m. ET.

A live audio webcast of the event will be accessible from the Investors and Media section of the Dicerna website at www.investors.dicerna.com. An archived replay will be available on the Company’s website following the event.

About Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) is a biopharmaceutical company focused on discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. Using our proprietary RNAi technology platform called GalXC™, Dicerna is committed to developing RNAi-based therapies with the potential to treat both rare and more prevalent diseases. By silencing disease-causing genes, Dicerna’s GalXC platform has the potential to address conditions that are difficult to treat with other modalities. Initially focused on hepatocytes, Dicerna has continued to innovate and is exploring new applications of its RNAi technology beyond the liver, targeting additional tissues and enabling new therapeutic applications. In addition to our own pipeline of core discovery and clinical candidates, Dicerna has established collaborative relationships with some of the world’s leading pharmaceutical companies, including Novo Nordisk A/S, Roche, Eli Lilly and Company, Alexion Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH and Alnylam Pharmaceuticals, Inc. Between Dicerna and our collaborative partners, we currently have more than 20 active discovery, preclinical or clinical programs focused on rare, cardiometabolic, viral, chronic liver and complement-mediated diseases, as well as neurodegeneration and pain. At Dicerna, our mission is to interfere – to silence genes, to fight disease, to restore heath. For more information, please visit www.dicerna.com.

Cautionary Note on Forward-Looking Statements
This press release includes forward-looking statements relating to the Company’s planned attendance at an investor conference, which may include discussion of the Company’s business, plans and research and development. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Applicable risks and uncertainties include those risks identified under the heading “Risk Factors” included in our most recent Form 10-Q filing and in other future filings with the SEC. The forward-looking statements contained in this press release reflect Dicerna's current views with respect to future events, and Dicerna does not undertake and specifically disclaims any obligation to update any forward-looking statements.

GalXC™ is a trademark of Dicerna Pharmaceuticals, Inc.

© Business Wire 2020

share with twitter share with LinkedIn share with facebook
All news about DICERNA PHARMACEUTICALS, INC.
10/23DICERNA PHARMACEUTICALS : Presents Positive New Interim Data from PHYOX3 Long-Te..
AQ
10/22DICERNA PHARMACEUTICALS INC : Other Events, Financial Statements and Exhibits (f..
AQ
10/22DICERNA PHARMACEUTICALS : Presents Positive New Interim Data From PHYOX™3 ..
BU
10/14DICERNA PHARMACEUTICALS : to Participate in the H.C. Wainwright Hepatitis B Viru..
AQ
10/14UFP TECHNOLOGIES : VBL Therapeutics Announces Appointment of Marc Kozin as Vice ..
AQ
10/13DICERNA PHARMACEUTICALS : to Participate in the H.C. Wainwright Hepatitis B Viru..
BU
10/12DICERNA PHARMACEUTICALS : to Present Nedosiran Data at American Society of Nephr..
AQ
10/09DICERNA PHARMACEUTICALS : to Present Nedosiran Data at American Society of Nephr..
BU
10/02DICERNA PHARMACEUTICALS : Reports Inducement Grants under Nasdaq Listing Rule 56..
AQ
10/01DICERNA PHARMACEUTICALS : Reports Inducement Grants Under Nasdaq Listing Rule 56..
BU
More news
Financials (USD)
Sales 2020 203 M - -
Net income 2020 -65,5 M - -
Net Debt 2020 - - -
P/E ratio 2020 -20,0x
Yield 2020 -
Capitalization 1 444 M 1 444 M -
Capi. / Sales 2020 7,11x
Capi. / Sales 2021 6,93x
Nbr of Employees 187
Free-Float 91,6%
Chart DICERNA PHARMACEUTICALS, INC.
Duration : Period :
Dicerna Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DICERNA PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Average target price 34,78 $
Last Close Price 19,39 $
Spread / Highest target 148%
Spread / Average Target 79,4%
Spread / Lowest Target 28,9%
EPS Revisions
Managers
NameTitle
Douglas M. Fambrough President, Chief Executive Officer & Director
J. Kevin Buchi Chairman
James B. Weissman Chief Operating Officer & Executive Vice President
Douglas W. Pagán Chief Financial Officer
Bob D. Brown Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
DICERNA PHARMACEUTICALS, INC.-11.98%1 444
GILEAD SCIENCES, INC.-6.45%76 214
REGENERON PHARMACEUTICALS54.42%61 014
VERTEX PHARMACEUTICALS-3.37%55 110
WUXI APPTEC CO., LTD.58.33%37 775
BEIGENE, LTD.80.38%27 097